slider

Pharma and biotech on a roll as drug approvals hit 18-year high

* U.S. FDA approves 41 novel medicines in 2014 vs 27 in 2013 * U.S. FDA approves 41 novel medicines in 2014 vs 27 in 2013 * New treatments for cancer and rare disease fuel rise * High cost of new drugs leads to tensions with insurers By Ben Hirschler LONDON, Jan 1 (Reuters) –(…)

More

Top 10 M&A Deals of 2014

Revived markets, inversions, and big pharma’s appetite for new therapies spur megamergers. 2014 could be a year for the history books. Many believe that we will never see another year with so many mergers and acquisitions. [© Yuri Arcurs – Fotolia.com] Just a few numbers show how far the value of 2014’s top deals involving(…)

More

Diversity Is Useless Without Inclusivity

HBR Blog Network Harvard Business Review by Christine M. Riordan  |   12:00 PM June 5, 2014 Over the past decade, organizations have worked hard to create diversity within their workforce. Diversity can bring many organizational benefits, including greater customer satisfaction, better market position, successful decision-making, an enhanced ability to reach strategic goals, improved organizational outcomes, and a stronger(…)

More

The FDA Step In to “guide” Drugmakers’ Digital Marketing Strategies

06-5-2014 |by  EDWARD C LAWRENCE   If you think the pharmaceutical industry’s direct-to-consumer advertising is limited largely to national nightly news broadcasts and geriatric magazines, think again. Brand-name drug manufacturers have gone fully digital, with significant implications for patients, physicians, and public and private payers. While most companies are rushing to implement digital marketing strategies, brand-name pharmaceuticals(…)

More

Telemedicine: The Future of Health Care

MICHAEL H. COHEN, ESQ. – FEB 2014 Sixty years ago, a family with a sick child could call their doctor, and, in a couple of hours, see him or her at the front curb, emerging with the well-known “black bag.” Times have changed, but at least when it comes to convenience, what was old is new again.(…)

More

Should the world go on a diet in 2014?

There has been a dramatic increase in the numbers of overweight or obese people in the past 30 years. Previously considered a problem in richer countries, the biggest rises are in middle income countries and the developing world. ‘Future Diets‘ traces how the changes in diet – more fat, more meat, more sugar and bigger(…)

More

International Business Tax Reform Discussion Draft

Chairman Max Baucus  / U.S. Senate Committee on Finance  11/19/13  As part of his work towards tax reform, Chairman Max Baucus is releasing a staff discussion draft today on international business tax reform. Many of the major features of our current international tax system were created in the 1960s and address a world that no longer exists.(…)

More

OUR SERVICE APPROACH

        Multinational Partnerships is dedicated to making life easier and more productive for organizations, expanding their business within the Americas We Provide: Evaluations of the internal competences, product and market scopes Thorough screening and feasibility analysis of the targeted countries and markets from diverse perspectives in order to identify and evaluate the(…)

More

Positive prospects for Latin American pharma

Positive prospects for Latin American pharma Latin America offers a healthy proposition for investors when compared to mature, stalling markets with poor growth predictions by Catarina Féria Latin America bounced back from the 2008 financial crisis and its economy is stronger than ever, due to GDP increases, high employment rates and the growth of a middle(…)

More

LATAM Healthcare Outlook

Latin America’s healthcare spending will resume its rise as a percentage of GDP, but market prospects will continue to be affected by patent disputes and currency shifts.

More